Skip to main content

Pharming Group announces it has entered into an exclusive licence agreement with NewBridge Pharmaceuticals (“NewBridge”) for the distribution of RUCONEST® (conestat alfa) in the Middle East and North Africa (“MENA”).


We look forward to continuing to expand the global reach of RUCONEST®, in line with our growth strategy, to serve HAE patients with unmet medical needs

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline